Tests KK3910 safety in healthy people and adults with high blood pressure
Tests the drug KK3910 against placebo in healthy adults and adults with high blood pressure.
Plain-language title generated from the registry record
Registry title: Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Key facts
- Where
- Hakata, Minato-ku, and Yodogawa, JapanSee the 3 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06823947, who can take part
Where in Japan
- SOUSEIKAI PS ClinicHakata, JapanNot yet recruiting
- Kitasato University Kitasato Institute HospitalMinato-ku, JapanTaking people
- Medical Corporation Heishinkai OPHAC HospitalYodogawa, JapanNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kyowa Kirin Co., Ltd.
- Trial code
- NCT06823947
- Record updated
- 1 July 2026
- Original description
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.Read full original descriptionShow less
A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.
Inclusion: Voluntary consent to participate in this study must be given (in writing); Japanese healthy adults or non-Asian healthy men 18 to < 55 years at the time of informed consent ( Japanese healthy adults 65 to < 80 years for the elderly cohort); BMI is within the specified range at screening; Voluntary consent to participate in this study must be given (in writing); Japanese patients with essential hypertension, aged 18 to <65 years at the time of informed consent; BMI is within the specified range at screening; Voluntary consent to participate in this study must be given (in writing); Japanese patients with essential hypertension, aged 18 to <80 years at the time of informed consent; BMI is within the specified range at screening.
Exclusion: History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator; History of or current drug allergy; History of or current alcoholism or drug addiction; infection within the specified period; Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study; History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator; History or of current drug allergy; History of or current alcoholism or drug addiction; infection within the specified period; Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study; History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator; History or of current drug allergy; History of or current alcoholism or drug addiction; infection within the specified period; Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study; Smoking within the specified period; Pregnant or breastfeeding patients, or patients willing to have a child during the study; Smoking within the specified period; Pregnant or breastfeeding patients, or patients willing to have a child during the study; Smoking within the specified period.